Evidence map›Paper›PMID 39666148›Full record

ArticleJournal of neurology2024

Longitudinal associations between cerebrospinal fluid glial activation markers, depression, and dopamine transporter availability in patients with Parkinson's disease.

Dehao Yang, Feng Chen, Junli Ren, Lingsheng Wang, Zhangjing Zhu, Zihao Wu, Qiaoqiao Jin, Yuwen Luo, Haoyang Huang, Baoyi Zhu and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Dehao Yang *Department of Neurology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Feng Chen *The Second School of Medicine, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Junli Ren *Department of Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Lingsheng WangThe First School of Medicine, School of Information and Engineering, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Zhangjing ZhuThe First School of Medicine, School of Information and Engineering, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Zihao WuThe First School of Medicine, School of Information and Engineering, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Qiaoqiao JinThe First School of Medicine, School of Information and Engineering, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Yuwen LuoThe First School of Medicine, School of Information and Engineering, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Haoyang HuangThe Second School of Medicine, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Baoyi ZhuThe School of Mental Health, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Yang ZhangThe First School of Medicine, School of Information and Engineering, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Yuchen LinThe First School of Medicine, School of Information and Engineering, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Linxuan ZhouThe First School of Medicine, School of Information and Engineering, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Guozhu MuDepartment of Radiology, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China. est0725@wmu.edu.cn.
Guangyong ChenDepartment of Neurology, The Third Affiliated Hospital of Wenzhou Medical University, No.108 Wansong Road, Wenzhou, 325000, Zhejiang, China. gychen6@126.com.ORCID http://orcid.org/0000-0003-1818-6280

Funding

Fundamental Research Funds for the Central Universities 2023FZZX05-02National Natural Science Foundation of China 82302081Zhejiang Provincial Natural Science Foundation of China LQ24H090003
6 · The paper itself

Abstract

backgroundDepression and decreased dopamine transporter (DAT) availability are prevalent in Parkinson's disease (PD), yet early predictive biomarkers are lacking. This study investigates the longitudinal associations between cerebrospinal fluid (CSF) neuroglial activation markers, sTREM2 and YKL-40, and depression, as well as DAT availability, in PD patients.

methodsWe analyzed data from 172 PD subjects and 80 matched healthy controls from a large longitudinal study. A generalized linear mixed-effects model assessed the longitudinal associations of CSF sTREM2 and YKL-40 with depression and DAT availability. Causal mediation analysis determined if DAT decline mediated the effects of sTREM2 and YKL-40 on depression.

resultsCross-sectional analysis revealed a negative correlation between CSF sTREM2 and baseline depression scores in PD patients. CSF YKL-40 negatively correlated with baseline left caudate nucleus, left anterior putamen, and right anterior putamen specific binding ratios (SBR). Longitudinally, higher baseline CSF sTREM2 predicted faster depression progression (β = 0.828, p < 0.001) and a rapid decline in right putamen SBR (β = 0.072, p = 0.016). Similarly, higher baseline CSF YKL-40 predicted faster depression progression (β = 0.586, p = 0.004) and a decline in left anterior putamen SBR (β = 0.058, p = 0.035). Causal mediation analysis indicated that baseline CSF sTREM2 accelerated depression progression via its effect on right putamen and right anterior putamen SBR (Indirect effect = 0.103, p = 0.020; Indirect effect = 0.129, p = 0.016).

conclusionCSF sTREM2 and YKL-40 are effective predictors for depression and DAT decline in PD, suggesting that neuroglial activation-induced dopaminergic neuron apoptosis significantly contributes to depression onset in PD.

Indexed as

Chitinase-3-Like Protein 1DepressionDopamine Plasma Membrane Transport ProteinsParkinson DiseaseAgedBiomarkersCross-Sectional StudiesFemaleHumansLongitudinal StudiesMaleMembrane GlycoproteinsMiddle AgedNeurogliaReceptors, ImmunologicBiomarkersCHI3L1 protein, humanChitinase-3-Like Protein 1Dopamine Plasma Membrane Transport ProteinsMembrane GlycoproteinsReceptors, ImmunologicTREM2 protein, humanDepressionDopamine transporter availabilityNeuroglial activation markersNeuroinflammationParkinson’s disease

Identifiers

PMID39666148

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.